Related Experiment Video

Updated: May 30, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Visceral leishmaniasis: immunology and prospects for a vaccine

P M Kaye1, T Aebischer

  • 1Centre for Immunology and Infection, Hull York Medical School and Department of Biology, University of York, York, UK. paul.kaye@york.ac.uk

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|August 20, 2011
PubMed

Insights

Human visceral leishmaniasis (HVL), a severe parasitic disease, causes over 50,000 deaths annually. This review covers HVL immunology and current vaccine development strategies.

Area of Science:

  • Tropical Medicine
  • Immunology
  • Parasitology
  • Vaccinology

Background:

  • Human visceral leishmaniasis (HVL) is the most severe form of leishmaniasis, a group of neglected tropical diseases caused by Leishmania parasites.
  • Primarily caused by Leishmania donovani and Leishmania infantum/chagasi, HVL results in over 50,000 fatalities annually.
  • Current drug treatments for HVL are expensive, and drug resistance is a growing concern.

Purpose of the Study:

  • To review the current understanding of the immunology of human visceral leishmaniasis.
  • To discuss the progress and status of vaccine development against HVL.

Main Methods:

  • Comprehensive literature review of existing research on HVL immunology.
  • Analysis of current vaccine development approaches and their efficacy.

Main Results:

  • Detailed examination of the host immune response in HVL.
  • Overview of various vaccine candidates and strategies being explored.
  • Identification of challenges and opportunities in HVL vaccine development.

Conclusions:

  • A deeper understanding of HVL immunology is crucial for effective vaccine design.
  • Vaccine development remains a critical but challenging area for controlling HVL.
  • Further research is needed to overcome existing hurdles and develop a viable HVL vaccine.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview